首页 > 最新文献

JAMA Psychiatry最新文献

英文 中文
Mental Health Care Support in Rural India: A Cluster Randomized Clinical Trial. 印度农村地区的心理保健支持:集群随机临床试验。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2305
Pallab K Maulik, Mercian Daniel, Siddhardha Devarapalli, Sudha Kallakuri, Amanpreet Kaur, Arpita Ghosh, Laurent Billot, Ankita Mukherjee, Rajesh Sagar, Sashi Kant, Susmita Chatterjee, Beverley M Essue, Usha Raman, Devarsetty Praveen, Graham Thornicroft, Shekhar Saxena, Anushka Patel, David Peiris
<p><strong>Importance: </strong>More than 150 million people in India need mental health care but few have access to affordable care, especially in rural areas.</p><p><strong>Objective: </strong>To determine whether a multifaceted intervention involving a digital health care model along with a community-based antistigma campaign leads to reduced depression risk and lower mental health-related stigma among adults residing in rural India.</p><p><strong>Design, setting, and participants: </strong>This parallel, cluster randomized, usual care-controlled trial was conducted from September 2020 to December 2021 with blinded follow-up assessments at 3, 6, and 12 months at 44 rural primary health centers across 3 districts in Haryana and Andhra Pradesh states in India. Adults aged 18 years and older at high risk of depression or self-harm defined by either a Patient Health Questionnaire-9 item (PHQ-9) score of 10 or greater, a Generalized Anxiety Disorder-7 item (GAD-7) score of 10 or greater, or a score of 2 or greater on the self-harm/suicide risk question on the PHQ-9. A second cohort of adults not at high risk were selected randomly from the remaining screened population. Data were cleaned and analyzed from April 2022 to February 2023.</p><p><strong>Interventions: </strong>The 12-month intervention included a community-based antistigma campaign involving all participants and a digital mental health intervention involving only participants at high risk. Primary health care workers were trained to identify and manage participants at high risk using the Mental Health Gap Action Programme guidelines from the World Health Organization.</p><p><strong>Main outcomes and measures: </strong>The 2 coprimary outcomes assessed at 12 months were mean PHQ-9 scores in the high-risk cohort and mean behavior scores in the combined high-risk and non-high-risk cohorts using the Mental Health Knowledge, Attitude, and Behavior scale.</p><p><strong>Results: </strong>Altogether, 9928 participants were recruited (3365 at high risk and 6563 not at high risk; 5638 [57%] female and 4290 [43%] male; mean [SD] age, 43 [16] years) with 9057 (91.2%) followed up at 12 months. Mean PHQ-9 scores at 12 months for the high-risk cohort were lower in the intervention vs control groups (2.77 vs 4.48; mean difference, -1.71; 95% CI, -2.53 to -0.89; P < .001). The remission rate in the high-risk cohort (PHQ-9 and GAD-7 scores <5 and no risk of self-harm) was higher in the intervention vs control group (74.7% vs 50.6%; odds ratio [OR], 2.88; 95% CI, 1.53 to 5.42; P = .001). Across both cohorts, there was no difference in 12-month behavior scores in the intervention vs control group (17.39 vs 17.74; mean difference, -0.35; 95% CI, -1.11 to 0.41; P = .36).</p><p><strong>Conclusions and relevance: </strong>A multifaceted intervention was effective in reducing depression risk but did not improve intended help-seeking behaviors for mental illness.</p><p><strong>Trial registration: </strong>Clinica
重要性印度有 1.5 亿多人需要心理健康护理,但很少有人能获得负担得起的护理,尤其是在农村地区:目的:确定涉及数字医疗模式的多方面干预措施以及基于社区的反污名化运动是否能降低印度农村成年人的抑郁风险并减少与心理健康相关的污名化:这项平行、分组随机、常规护理对照试验于 2020 年 9 月至 2021 年 12 月在印度哈里亚纳邦和安得拉邦 3 个地区的 44 个农村初级保健中心进行,并在 3、6 和 12 个月时进行盲法随访评估。患者健康问卷-9(PHQ-9)项目得分达到或超过 10 分,广泛性焦虑症-7(GAD-7)项目得分达到或超过 10 分,或 PHQ-9 中自残/自杀风险问题得分达到或超过 2 分,即为抑郁症或自残高风险 18 岁及以上成年人。从剩余的筛查人群中随机抽取了第二批非高风险成人。从 2022 年 4 月至 2023 年 2 月对数据进行清理和分析:为期 12 个月的干预措施包括一项由所有参与者参与的社区反污名化运动和一项仅由高风险参与者参与的数字心理健康干预措施。对初级卫生保健工作者进行了培训,以使用世界卫生组织的心理健康差距行动方案指南来识别和管理高风险参与者:在 12 个月内评估的 2 项主要结果是高风险人群的 PHQ-9 平均得分,以及高风险和非高风险人群使用心理健康知识、态度和行为量表的平均行为得分:共招募了 9928 名参与者(高危 3365 人,非高危 6563 人;女性 5638 人 [57%],男性 4290 人 [43%];平均 [SD] 年龄 43 [16] 岁),其中 9057 人(91.2%)接受了 12 个月的随访。干预组与对照组相比,高危人群在 12 个月后的 PHQ-9 平均得分较低(2.77 vs 4.48;平均差异,-1.71;95% CI,-2.53 to -0.89;P 结论及意义:多方面干预能有效降低抑郁风险,但并不能改善精神疾病的预期求助行为:印度临床试验注册中心:CTRI/2018/08/015355.
{"title":"Mental Health Care Support in Rural India: A Cluster Randomized Clinical Trial.","authors":"Pallab K Maulik, Mercian Daniel, Siddhardha Devarapalli, Sudha Kallakuri, Amanpreet Kaur, Arpita Ghosh, Laurent Billot, Ankita Mukherjee, Rajesh Sagar, Sashi Kant, Susmita Chatterjee, Beverley M Essue, Usha Raman, Devarsetty Praveen, Graham Thornicroft, Shekhar Saxena, Anushka Patel, David Peiris","doi":"10.1001/jamapsychiatry.2024.2305","DOIUrl":"10.1001/jamapsychiatry.2024.2305","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;More than 150 million people in India need mental health care but few have access to affordable care, especially in rural areas.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine whether a multifaceted intervention involving a digital health care model along with a community-based antistigma campaign leads to reduced depression risk and lower mental health-related stigma among adults residing in rural India.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This parallel, cluster randomized, usual care-controlled trial was conducted from September 2020 to December 2021 with blinded follow-up assessments at 3, 6, and 12 months at 44 rural primary health centers across 3 districts in Haryana and Andhra Pradesh states in India. Adults aged 18 years and older at high risk of depression or self-harm defined by either a Patient Health Questionnaire-9 item (PHQ-9) score of 10 or greater, a Generalized Anxiety Disorder-7 item (GAD-7) score of 10 or greater, or a score of 2 or greater on the self-harm/suicide risk question on the PHQ-9. A second cohort of adults not at high risk were selected randomly from the remaining screened population. Data were cleaned and analyzed from April 2022 to February 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;The 12-month intervention included a community-based antistigma campaign involving all participants and a digital mental health intervention involving only participants at high risk. Primary health care workers were trained to identify and manage participants at high risk using the Mental Health Gap Action Programme guidelines from the World Health Organization.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The 2 coprimary outcomes assessed at 12 months were mean PHQ-9 scores in the high-risk cohort and mean behavior scores in the combined high-risk and non-high-risk cohorts using the Mental Health Knowledge, Attitude, and Behavior scale.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Altogether, 9928 participants were recruited (3365 at high risk and 6563 not at high risk; 5638 [57%] female and 4290 [43%] male; mean [SD] age, 43 [16] years) with 9057 (91.2%) followed up at 12 months. Mean PHQ-9 scores at 12 months for the high-risk cohort were lower in the intervention vs control groups (2.77 vs 4.48; mean difference, -1.71; 95% CI, -2.53 to -0.89; P &lt; .001). The remission rate in the high-risk cohort (PHQ-9 and GAD-7 scores &lt;5 and no risk of self-harm) was higher in the intervention vs control group (74.7% vs 50.6%; odds ratio [OR], 2.88; 95% CI, 1.53 to 5.42; P = .001). Across both cohorts, there was no difference in 12-month behavior scores in the intervention vs control group (17.39 vs 17.74; mean difference, -0.35; 95% CI, -1.11 to 0.41; P = .36).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;A multifaceted intervention was effective in reducing depression risk but did not improve intended help-seeking behaviors for mental illness.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;Clinica","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Informant Effect on Placebo Response in Mental Disorders-Reply. 精神障碍患者对安慰剂反应的知情者效应--回复。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2868
Tom Bschor, Christopher Baethge
{"title":"Informant Effect on Placebo Response in Mental Disorders-Reply.","authors":"Tom Bschor, Christopher Baethge","doi":"10.1001/jamapsychiatry.2024.2868","DOIUrl":"10.1001/jamapsychiatry.2024.2868","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Psychiatry. 美国医学会精神病学杂志》。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2023.3948
{"title":"JAMA Psychiatry.","authors":"","doi":"10.1001/jamapsychiatry.2023.3948","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2023.3948","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neighborhood Resources Associated With Psychological Trajectories and Neural Reactivity to Reward After Trauma. 邻里资源与创伤后的心理轨迹和神经对奖赏的反应有关。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2148
E Kate Webb, Jennifer S Stevens, Timothy D Ely, Lauren A M Lebois, Sanne J H van Rooij, Steven E Bruce, Stacey L House, Francesca L Beaudoin, Xinming An, Thomas C Neylan, Gari D Clifford, Sarah D Linnstaedt, Laura T Germine, Kenneth A Bollen, Scott L Rauch, John P Haran, Alan B Storrow, Christopher Lewandowski, Paul I Musey, Phyllis L Hendry, Sophia Sheikh, Christopher W Jones, Brittany E Punches, Robert A Swor, Vishnu P Murty, Lauren A Hudak, Jose L Pascual, Mark J Seamon, Elizabeth M Datner, Claire Pearson, David A Peak, Robert M Domeier, Niels K Rathlev, Brian J O'Neil, Paulina Sergot, Leon D Sanchez, Jutta Joormann, Diego A Pizzagalli, Steven E Harte, Ronald C Kessler, Karestan C Koenen, Kerry J Ressler, Samuel A McLean, Nathaniel G Harnett
<p><strong>Importance: </strong>Research on resilience after trauma has often focused on individual-level factors (eg, ability to cope with adversity) and overlooked influential neighborhood-level factors that may help mitigate the development of posttraumatic stress disorder (PTSD).</p><p><strong>Objective: </strong>To investigate whether an interaction between residential greenspace and self-reported individual resources was associated with a resilient PTSD trajectory (ie, low/no symptoms) and to test if the association between greenspace and PTSD trajectory was mediated by neural reactivity to reward.</p><p><strong>Design, setting, and participants: </strong>As part of a longitudinal cohort study, trauma survivors were recruited from emergency departments across the US. Two weeks after trauma, a subset of participants underwent functional magnetic resonance imaging during a monetary reward task. Study data were analyzed from January to November 2023.</p><p><strong>Exposures: </strong>Residential greenspace within a 100-m buffer of each participant's home address was derived from satellite imagery and quantified using the Normalized Difference Vegetation Index and perceived individual resources measured by the Connor-Davidson Resilience Scale (CD-RISC).</p><p><strong>Main outcome and measures: </strong>PTSD symptom severity measured at 2 weeks, 8 weeks, 3 months, and 6 months after trauma. Neural responses to monetary reward in reward-related regions (ie, amygdala, nucleus accumbens, orbitofrontal cortex) was a secondary outcome. Covariates included both geocoded (eg, area deprivation index) and self-reported characteristics (eg, childhood maltreatment, income).</p><p><strong>Results: </strong>In 2597 trauma survivors (mean [SD] age, 36.5 [13.4] years; 1637 female [63%]; 1304 non-Hispanic Black [50.2%], 289 Hispanic [11.1%], 901 non-Hispanic White [34.7%], 93 non-Hispanic other race [3.6%], and 10 missing/unreported [0.4%]), 6 PTSD trajectories (resilient, nonremitting high, nonremitting moderate, slow recovery, rapid recovery, delayed) were identified through latent-class mixed-effect modeling. Multinominal logistic regressions revealed that for individuals with higher CD-RISC scores, greenspace was associated with a greater likelihood of assignment in a resilient trajectory compared with nonremitting high (Wald z test = -3.92; P < .001), nonremitting moderate (Wald z test = -2.24; P = .03), or slow recovery (Wald z test = -2.27; P = .02) classes. Greenspace was also associated with greater neural reactivity to reward in the amygdala (n = 288; t277 = 2.83; adjusted P value = 0.02); however, reward reactivity did not differ by PTSD trajectory.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, greenspace and self-reported individual resources were significantly associated with PTSD trajectories. These findings suggest that factors at multiple ecological levels may contribute to the likelihood of resiliency to PTSD after tra
重要性:有关创伤后复原力的研究通常侧重于个人层面的因素(如应对逆境的能力),而忽略了可能有助于缓解创伤后应激障碍(PTSD)发展的有影响力的邻里层面的因素:目的:研究居住区绿地与自我报告的个人资源之间的相互作用是否与创伤后应激障碍的恢复轨迹(即低症状/无症状)相关,并检验绿地与创伤后应激障碍轨迹之间的关联是否通过神经对奖赏的反应性进行调节:作为纵向队列研究的一部分,研究人员从美国各地的急诊科招募创伤幸存者。创伤两周后,一部分参与者在接受金钱奖励任务时接受了功能磁共振成像检查。研究数据分析时间为 2023 年 1 月至 11 月:每位参与者家庭住址 100 米缓冲区内的住宅绿地由卫星图像得出,并使用归一化差异植被指数进行量化,感知的个人资源由康纳-戴维森复原力量表(CD-RISC)测量:创伤后应激障碍症状严重程度分别在创伤后 2 周、8 周、3 个月和 6 个月进行测量。次要结果包括奖赏相关区域(即杏仁核、伏隔核、眶额皮层)对金钱奖赏的神经反应。协变量包括地理编码(如地区贫困指数)和自我报告特征(如儿童虐待、收入):结果:2597 名创伤幸存者(平均 [SD] 年龄为 36.5 [13.4] 岁;1637 名女性 [63%];1304 名非西班牙裔黑人 [50.2%],289 名西班牙裔 [11.1%],901 名非西班牙裔白人 [34.7%],93 名非西班牙裔其他种族 [3.6%],10 名缺失/未报告。6%],10 人缺失/未报告[0.4%]),通过潜类混合效应建模确定了 6 种创伤后应激障碍轨迹(恢复能力强、非缓解性高、非缓解性中等、缓慢恢复、快速恢复、延迟)。多项式逻辑回归显示,对于 CD-RISC 得分较高的个体,绿地与非缓解高分相比,更有可能被分配到恢复性轨迹中(Wald z test = -3.92;P 结论及相关性:在这项队列研究中,绿地和自我报告的个人资源与创伤后应激障碍轨迹有显著相关性。这些研究结果表明,多个生态层面的因素可能有助于创伤后应激障碍的恢复。
{"title":"Neighborhood Resources Associated With Psychological Trajectories and Neural Reactivity to Reward After Trauma.","authors":"E Kate Webb, Jennifer S Stevens, Timothy D Ely, Lauren A M Lebois, Sanne J H van Rooij, Steven E Bruce, Stacey L House, Francesca L Beaudoin, Xinming An, Thomas C Neylan, Gari D Clifford, Sarah D Linnstaedt, Laura T Germine, Kenneth A Bollen, Scott L Rauch, John P Haran, Alan B Storrow, Christopher Lewandowski, Paul I Musey, Phyllis L Hendry, Sophia Sheikh, Christopher W Jones, Brittany E Punches, Robert A Swor, Vishnu P Murty, Lauren A Hudak, Jose L Pascual, Mark J Seamon, Elizabeth M Datner, Claire Pearson, David A Peak, Robert M Domeier, Niels K Rathlev, Brian J O'Neil, Paulina Sergot, Leon D Sanchez, Jutta Joormann, Diego A Pizzagalli, Steven E Harte, Ronald C Kessler, Karestan C Koenen, Kerry J Ressler, Samuel A McLean, Nathaniel G Harnett","doi":"10.1001/jamapsychiatry.2024.2148","DOIUrl":"10.1001/jamapsychiatry.2024.2148","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Research on resilience after trauma has often focused on individual-level factors (eg, ability to cope with adversity) and overlooked influential neighborhood-level factors that may help mitigate the development of posttraumatic stress disorder (PTSD).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate whether an interaction between residential greenspace and self-reported individual resources was associated with a resilient PTSD trajectory (ie, low/no symptoms) and to test if the association between greenspace and PTSD trajectory was mediated by neural reactivity to reward.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;As part of a longitudinal cohort study, trauma survivors were recruited from emergency departments across the US. Two weeks after trauma, a subset of participants underwent functional magnetic resonance imaging during a monetary reward task. Study data were analyzed from January to November 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;Residential greenspace within a 100-m buffer of each participant's home address was derived from satellite imagery and quantified using the Normalized Difference Vegetation Index and perceived individual resources measured by the Connor-Davidson Resilience Scale (CD-RISC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcome and measures: &lt;/strong&gt;PTSD symptom severity measured at 2 weeks, 8 weeks, 3 months, and 6 months after trauma. Neural responses to monetary reward in reward-related regions (ie, amygdala, nucleus accumbens, orbitofrontal cortex) was a secondary outcome. Covariates included both geocoded (eg, area deprivation index) and self-reported characteristics (eg, childhood maltreatment, income).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In 2597 trauma survivors (mean [SD] age, 36.5 [13.4] years; 1637 female [63%]; 1304 non-Hispanic Black [50.2%], 289 Hispanic [11.1%], 901 non-Hispanic White [34.7%], 93 non-Hispanic other race [3.6%], and 10 missing/unreported [0.4%]), 6 PTSD trajectories (resilient, nonremitting high, nonremitting moderate, slow recovery, rapid recovery, delayed) were identified through latent-class mixed-effect modeling. Multinominal logistic regressions revealed that for individuals with higher CD-RISC scores, greenspace was associated with a greater likelihood of assignment in a resilient trajectory compared with nonremitting high (Wald z test = -3.92; P &lt; .001), nonremitting moderate (Wald z test = -2.24; P = .03), or slow recovery (Wald z test = -2.27; P = .02) classes. Greenspace was also associated with greater neural reactivity to reward in the amygdala (n = 288; t277 = 2.83; adjusted P value = 0.02); however, reward reactivity did not differ by PTSD trajectory.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this cohort study, greenspace and self-reported individual resources were significantly associated with PTSD trajectories. These findings suggest that factors at multiple ecological levels may contribute to the likelihood of resiliency to PTSD after tra","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mindfulness-Based Cognitive Therapy's Untapped Potential. 正念认知疗法尚未开发的潜能。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2741
Jesus Montero-Marin, Anne Maj van der Velden, Willem Kuyken
{"title":"Mindfulness-Based Cognitive Therapy's Untapped Potential.","authors":"Jesus Montero-Marin, Anne Maj van der Velden, Willem Kuyken","doi":"10.1001/jamapsychiatry.2024.2741","DOIUrl":"10.1001/jamapsychiatry.2024.2741","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the Structure in Mental Disorder Presentations. 揭开精神障碍表现形式的结构面纱。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2047
Tobias R Spiller, Or Duek, Markus Helmer, John D Murray, Elliot Fielstein, Robert H Pietrzak, Roland von Känel, Ilan Harpaz-Rotem

Importance: DSM criteria are polythetic, allowing for heterogeneity of symptoms among individuals with the same disorder. In empirical research, most combinations were not found or only rarely found, prompting criticism of this heterogeneity.

Objective: To elaborate how symptom-based definitions and assessments contribute to a distinct probability pattern for the occurrence of symptom combinations.

Design, setting, and participants: This cross-sectional study involved a theoretical argument, simulation, and secondary data analysis of 4 preexisting datasets, each consisting of symptoms from 1 of the following syndromes: posttraumatic stress disorder, depression, schizophrenia, and anxiety. Data were obtained from various sources, including the National Institute of Mental Health Data Archive and Department of Veteran Affairs. A total of 155 474 participants were included (individual studies were 3930 to 63 742 individuals in size). Data were analyzed between July 2021 and January 2024.

Exposure: For each participant, the presence or absence of each assessed symptom and their combination was determined. The number of all combinations and their individual frequencies were assessed.

Main outcome and measure: Probability or frequency of unique symptom combinations and their distribution.

Results: Among the 155 474 participants, the mean (SD) age was 47.5 (14.8) years; 33 933 (21.8%) self-identified as female and 121 541 (78.2%) as male. Because of the interrelation between symptoms, some symptom combinations were significantly more likely than others. The distribution of the combinations' probability was heavily skewed with most combinations having a very low probability. Across all 4 empirical samples, the 1% most common combinations were prevalent in a total of 33.1% to 78.6% of the corresponding sample. At the same time, many combinations (ranging from 41.7% to 99.8%) were reported by less than 1% of the sample.

Conclusions and relevance: This study found that within-disorder symptom heterogeneity followed a specific pattern consisting of few prevalent, prototypical combinations and numerous combinations with a very low probability of occurrence. Future discussions about the revision of diagnostic criteria should take this specific pattern into account by focusing not only on the absolute number of symptom combinations but also on their individual and cumulative probabilities. Findings from clinical populations using common diagnostic criteria may have limited generalizability to the large group of individuals with a low-probability symptom combination.

重要性:DSM 标准是综合标准,允许患有相同障碍的个体出现不同的症状。在实证研究中,大多数症状组合未被发现或仅在极少数情况下被发现,从而引发了对这种异质性的批评:阐述基于症状的定义和评估如何导致症状组合出现的独特概率模式:这项横断面研究包括理论论证、模拟以及对 4 个已有数据集的二次数据分析,每个数据集由以下综合征中的一种症状组成:创伤后应激障碍、抑郁症、精神分裂症和焦虑症。数据来源多样,包括美国国家心理健康研究所数据档案和退伍军人事务部。共纳入 155 474 名参与者(单项研究的规模为 3930 到 63 742 人)。数据分析时间为 2021 年 7 月至 2024 年 1 月:对于每位参与者,确定其是否出现每种评估症状及其组合。评估所有组合的数量及其各自的频率:主要结果和测量:独特症状组合的概率或频率及其分布:在 155 474 名参与者中,平均(标清)年龄为 47.5(14.8)岁;33 933 人(21.8%)自认为是女性,121 541 人(78.2%)自认为是男性。由于症状之间的相互关系,某些症状组合的可能性明显高于其他症状组合。症状组合的概率分布严重偏斜,大多数症状组合的概率非常低。在所有 4 个经验样本中,最常见的 1%的症状组合在相应样本中的比例从 33.1%到 78.6%不等。与此同时,许多组合(从 41.7% 到 99.8%)在不到 1%的样本中出现:本研究发现,障碍内症状异质性遵循一种特定的模式,包括少数普遍存在的典型组合和大量出现概率极低的组合。今后有关诊断标准修订的讨论应考虑到这一特定模式,不仅要关注症状组合的绝对数量,还要关注其个体和累积概率。使用通用诊断标准的临床人群的研究结果可能对大量具有低概率症状组合的个体具有有限的普遍性。
{"title":"Unveiling the Structure in Mental Disorder Presentations.","authors":"Tobias R Spiller, Or Duek, Markus Helmer, John D Murray, Elliot Fielstein, Robert H Pietrzak, Roland von Känel, Ilan Harpaz-Rotem","doi":"10.1001/jamapsychiatry.2024.2047","DOIUrl":"10.1001/jamapsychiatry.2024.2047","url":null,"abstract":"<p><strong>Importance: </strong>DSM criteria are polythetic, allowing for heterogeneity of symptoms among individuals with the same disorder. In empirical research, most combinations were not found or only rarely found, prompting criticism of this heterogeneity.</p><p><strong>Objective: </strong>To elaborate how symptom-based definitions and assessments contribute to a distinct probability pattern for the occurrence of symptom combinations.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study involved a theoretical argument, simulation, and secondary data analysis of 4 preexisting datasets, each consisting of symptoms from 1 of the following syndromes: posttraumatic stress disorder, depression, schizophrenia, and anxiety. Data were obtained from various sources, including the National Institute of Mental Health Data Archive and Department of Veteran Affairs. A total of 155 474 participants were included (individual studies were 3930 to 63 742 individuals in size). Data were analyzed between July 2021 and January 2024.</p><p><strong>Exposure: </strong>For each participant, the presence or absence of each assessed symptom and their combination was determined. The number of all combinations and their individual frequencies were assessed.</p><p><strong>Main outcome and measure: </strong>Probability or frequency of unique symptom combinations and their distribution.</p><p><strong>Results: </strong>Among the 155 474 participants, the mean (SD) age was 47.5 (14.8) years; 33 933 (21.8%) self-identified as female and 121 541 (78.2%) as male. Because of the interrelation between symptoms, some symptom combinations were significantly more likely than others. The distribution of the combinations' probability was heavily skewed with most combinations having a very low probability. Across all 4 empirical samples, the 1% most common combinations were prevalent in a total of 33.1% to 78.6% of the corresponding sample. At the same time, many combinations (ranging from 41.7% to 99.8%) were reported by less than 1% of the sample.</p><p><strong>Conclusions and relevance: </strong>This study found that within-disorder symptom heterogeneity followed a specific pattern consisting of few prevalent, prototypical combinations and numerous combinations with a very low probability of occurrence. Future discussions about the revision of diagnostic criteria should take this specific pattern into account by focusing not only on the absolute number of symptom combinations but also on their individual and cumulative probabilities. Findings from clinical populations using common diagnostic criteria may have limited generalizability to the large group of individuals with a low-probability symptom combination.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperalgesia in Patients With a History of Opioid Use Disorder: A Systematic Review and Meta-Analysis. 有阿片类药物使用障碍史患者的痛觉减退:系统回顾与元分析》。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2176
Martin Trøstheim, Marie Eikemo

Importance: Short-term and long-term opioid treatment have been associated with increased pain sensitivity (ie, opioid-induced hyperalgesia). Treatment of opioid use disorder (OUD) mainly involves maintenance with methadone and buprenorphine, and observations of heightened cold pain sensitivity among patients are often considered evidence of opioid-induced hyperalgesia.

Objective: To critically examine the evidence that hyperalgesia in patients with OUD is related to opioid use.

Data sources: Web of Science, PubMed, and Embase between March 1, 2023, and April 12, 2024, were searched.

Study selection: Studies assessing cold pressor test (CPT) pain responses during treatment seeking, pharmacological treatment, or abstinence in patients with OUD history were included.

Data extraction and synthesis: Multilevel random-effects models with robust variance estimation were used for all analyses. Study quality was rated with the JBI checklist. Funnel plots and Egger regression tests were used to assess reporting bias.

Main outcomes and measures: Main outcomes were pain threshold, tolerance, and intensity in patients and healthy controls, and unstandardized, standardized (Hedges g), and percentage differences (%Δ) in these measures between patients and controls. The association between pain sensitivity and opioid tolerance, withdrawal, and abstinence indices was tested with meta-regression.

Results: Thirty-nine studies (1385 patients, 741 controls) met the inclusion criteria. Most studies reported CPT data on patients undergoing opioid agonist treatment. These patients had a mean 2- to 3-seconds lower pain threshold (95% CI, -4 to -1; t test P = .01; %Δ, -22%; g = -0.5) and 29-seconds lower pain tolerance (95% CI, -39 to -18; t test P < .001; %Δ, -52%; g = -0.9) than controls. Egger tests suggested that these differences may be overestimated. There were some concerns of bias due to inadequate sample matching and participant dropout. Meta-regressions yielded no clear support for hyperalgesia being opioid related.

Conclusion and relevance: Patients receiving opioid agonist treatment for OUD are hypersensitive to cold pain. It remains unclear whether hyperalgesia develops prior to, independent of, or as a result of long-term opioid treatment. Regardless, future studies should investigate the impact of hyperalgesia on patients' well-being and treatment outcomes.

重要性:短期和长期阿片类药物治疗与疼痛敏感性增加(即阿片类药物引起的痛觉减退)有关。阿片类药物使用障碍(OUD)的治疗主要包括美沙酮和丁丙诺啡的维持治疗,而观察到患者对冷痛的敏感性增加通常被认为是阿片类药物诱发痛觉减退的证据:批判性地研究 OUD 患者的痛觉减退与阿片类药物使用有关的证据:数据来源:检索了2023年3月1日至2024年4月12日期间的Web of Science、PubMed和Embase:研究选择:纳入评估有 OUD 病史的患者在寻求治疗、药物治疗或戒断期间的冷压试验(CPT)疼痛反应的研究:所有分析均采用稳健方差估计的多层次随机效应模型。研究质量采用 JBI 检查表进行评定。漏斗图和 Egger 回归检验用于评估报告偏倚:主要结果为患者和健康对照组的疼痛阈值、耐受性和强度,以及患者和对照组之间这些指标的非标准化、标准化(Hedges g)和百分比差异(%Δ)。通过元回归检验了疼痛敏感性与阿片类药物耐受性、戒断和禁欲指数之间的关联:39项研究(1385名患者,741名对照组)符合纳入标准。大多数研究报告了正在接受阿片类激动剂治疗的患者的 CPT 数据。这些患者的疼痛阈值平均降低了 2 至 3 秒(95% CI,-4 至 -1;t 检验 P = .01;%Δ,-22%;g = -0.5),疼痛耐受性降低了 29 秒(95% CI,-39 至 -18;t 检验 P 结论及相关性:接受阿片受体激动剂治疗的 OUD 患者对冷痛过敏。目前尚不清楚这种痛觉减退是在长期阿片类药物治疗之前出现的,还是独立于长期阿片类药物治疗之外的结果。无论如何,未来的研究都应探讨痛觉减退对患者福祉和治疗效果的影响。
{"title":"Hyperalgesia in Patients With a History of Opioid Use Disorder: A Systematic Review and Meta-Analysis.","authors":"Martin Trøstheim, Marie Eikemo","doi":"10.1001/jamapsychiatry.2024.2176","DOIUrl":"10.1001/jamapsychiatry.2024.2176","url":null,"abstract":"<p><strong>Importance: </strong>Short-term and long-term opioid treatment have been associated with increased pain sensitivity (ie, opioid-induced hyperalgesia). Treatment of opioid use disorder (OUD) mainly involves maintenance with methadone and buprenorphine, and observations of heightened cold pain sensitivity among patients are often considered evidence of opioid-induced hyperalgesia.</p><p><strong>Objective: </strong>To critically examine the evidence that hyperalgesia in patients with OUD is related to opioid use.</p><p><strong>Data sources: </strong>Web of Science, PubMed, and Embase between March 1, 2023, and April 12, 2024, were searched.</p><p><strong>Study selection: </strong>Studies assessing cold pressor test (CPT) pain responses during treatment seeking, pharmacological treatment, or abstinence in patients with OUD history were included.</p><p><strong>Data extraction and synthesis: </strong>Multilevel random-effects models with robust variance estimation were used for all analyses. Study quality was rated with the JBI checklist. Funnel plots and Egger regression tests were used to assess reporting bias.</p><p><strong>Main outcomes and measures: </strong>Main outcomes were pain threshold, tolerance, and intensity in patients and healthy controls, and unstandardized, standardized (Hedges g), and percentage differences (%Δ) in these measures between patients and controls. The association between pain sensitivity and opioid tolerance, withdrawal, and abstinence indices was tested with meta-regression.</p><p><strong>Results: </strong>Thirty-nine studies (1385 patients, 741 controls) met the inclusion criteria. Most studies reported CPT data on patients undergoing opioid agonist treatment. These patients had a mean 2- to 3-seconds lower pain threshold (95% CI, -4 to -1; t test P = .01; %Δ, -22%; g = -0.5) and 29-seconds lower pain tolerance (95% CI, -39 to -18; t test P < .001; %Δ, -52%; g = -0.9) than controls. Egger tests suggested that these differences may be overestimated. There were some concerns of bias due to inadequate sample matching and participant dropout. Meta-regressions yielded no clear support for hyperalgesia being opioid related.</p><p><strong>Conclusion and relevance: </strong>Patients receiving opioid agonist treatment for OUD are hypersensitive to cold pain. It remains unclear whether hyperalgesia develops prior to, independent of, or as a result of long-term opioid treatment. Regardless, future studies should investigate the impact of hyperalgesia on patients' well-being and treatment outcomes.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People. COVID-19 与接种疫苗和未接种疫苗者的精神疾病。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2339
Venexia M Walker, Praveetha Patalay, Jose Ignacio Cuitun Coronado, Rachel Denholm, Harriet Forbes, Jean Stafford, Bettina Moltrecht, Tom Palmer, Alex Walker, Ellen J Thompson, Kurt Taylor, Genevieve Cezard, Elsie M F Horne, Yinghui Wei, Marwa Al Arab, Rochelle Knight, Louis Fisher, Jon Massey, Simon Davy, Amir Mehrkar, Seb Bacon, Ben Goldacre, Angela Wood, Nishi Chaturvedi, John Macleod, Ann John, Jonathan A C Sterne
<p><strong>Importance: </strong>Associations have been found between COVID-19 and subsequent mental illness in both hospital- and population-based studies. However, evidence regarding which mental illnesses are associated with COVID-19 by vaccination status in these populations is limited.</p><p><strong>Objective: </strong>To determine which mental illnesses are associated with diagnosed COVID-19 by vaccination status in both hospitalized patients and the general population.</p><p><strong>Design, setting, and participants: </strong>This study was conducted in 3 cohorts, 1 before vaccine availability followed during the wild-type/Alpha variant eras (January 2020-June 2021) and 2 (vaccinated and unvaccinated) during the Delta variant era (June-December 2021). With National Health Service England approval, OpenSAFELY-TPP was used to access linked data from 24 million people registered with general practices in England using TPP SystmOne. People registered with a GP in England for at least 6 months and alive with known age between 18 and 110 years, sex, deprivation index information, and region at baseline were included. People were excluded if they had COVID-19 before baseline. Data were analyzed from July 2022 to June 2024.</p><p><strong>Exposure: </strong>Confirmed COVID-19 diagnosis recorded in primary care secondary care, testing data, or the death registry.</p><p><strong>Main outcomes and measures: </strong>Adjusted hazard ratios (aHRs) comparing the incidence of mental illnesses after diagnosis of COVID-19 with the incidence before or without COVID-19 for depression, serious mental illness, general anxiety, posttraumatic stress disorder, eating disorders, addiction, self-harm, and suicide.</p><p><strong>Results: </strong>The largest cohort, the pre-vaccine availability cohort, included 18 648 606 people (9 363 710 [50.2%] female and 9 284 896 [49.8%] male) with a median (IQR) age of 49 (34-64) years. The vaccinated cohort included 14 035 286 individuals (7 308 556 [52.1%] female and 6 726 730 [47.9%] male) with a median (IQR) age of 53 (38-67) years. The unvaccinated cohort included 3 242 215 individuals (1 363 401 [42.1%] female and 1 878 814 [57.9%] male) with a median (IQR) age of 35 (27-46) years. Incidence of most outcomes was elevated during weeks 1 through 4 after COVID-19 diagnosis, compared with before or without COVID-19, in each cohort. Incidence of mental illnesses was lower in the vaccinated cohort compared with the pre-vaccine availability and unvaccinated cohorts: aHRs for depression and serious mental illness during weeks 1 through 4 after COVID-19 were 1.93 (95% CI, 1.88-1.98) and 1.49 (95% CI, 1.41-1.57) in the pre-vaccine availability cohort and 1.79 (95% CI, 1.68-1.90) and 1.45 (95% CI, 1.27-1.65) in the unvaccinated cohort compared with 1.16 (95% CI, 1.12-1.20) and 0.91 (95% CI, 0.85-0.98) in the vaccinated cohort. Elevation in incidence was higher and persisted longer after hospitalization for COVID-19.</p><p><strong>Conc
重要性:在基于医院和人群的研究中发现,COVID-19 与随后的精神疾病之间存在关联。然而,在这些人群中,根据疫苗接种情况确定哪些精神疾病与 COVID-19 相关的证据却很有限:目的:根据住院患者和普通人群的疫苗接种情况,确定哪些精神疾病与确诊的 COVID-19 相关:本研究在 3 个队列中进行,1 个队列在疫苗上市前,在野生型/阿尔法变异时代(2020 年 1 月至 2021 年 6 月)进行跟踪,2 个队列(已接种疫苗和未接种疫苗)在德尔塔变异时代(2021 年 6 月至 12 月)进行跟踪。经英格兰国家卫生服务局批准,OpenSAFELY-TPP 用于访问使用 TPP SystmOne 在英格兰全科诊所登记的 2400 万人的链接数据。研究对象包括在英格兰全科医生处登记至少 6 个月,且已知年龄在 18 至 110 岁之间、性别、贫困指数信息和基线地区的在世者。如果在基线前已感染 COVID-19,则排除在外。数据分析时间为 2022 年 7 月至 2024 年 6 月:主要结果和测量指标:在抑郁症、严重精神疾病、一般焦虑症、创伤后应激障碍、进食障碍、成瘾、自残和自杀方面,比较确诊COVID-19后与确诊前或未确诊COVID-19前的精神疾病发病率的调整危险比(aHRs):最大的队列(疫苗接种前队列)包括 18 648 606 人(女性 9 363 710 [50.2%] ,男性 9 284 896 [49.8%]),中位数(IQR)年龄为 49(34-64)岁。接种疫苗的人群包括 14 035 286 人(女性 7 308 556 [52.1%] 人,男性 6 726 730 [47.9%]人),年龄中位数(IQR)为 53(38-67)岁。未接种疫苗的人群包括 3 242 215 人(女性 1 363 401 人 [42.1%] ,男性 1 878 814 人 [57.9%]),年龄中位数(IQR)为 35(27-46)岁。与确诊 COVID-19 之前或未确诊 COVID-19 之前相比,在确诊 COVID-19 后的第 1 至 4 周,每个队列中大多数结果的发生率都有所升高。与接种疫苗前和未接种疫苗的队列相比,接种疫苗队列的精神疾病发病率较低:在接种 COVID-19 后的第 1 至 4 周,抑郁症和严重精神疾病的 aHR 分别为 1.93(95% CI,1.88-1.98)和 1.49(95% CI,1.49-1.98)。98)和 1.49(95% CI,1.41-1.57),未接种疫苗队列为 1.79(95% CI,1.68-1.90)和 1.45(95% CI,1.27-1.65),而接种疫苗队列为 1.16(95% CI,1.12-1.20)和 0.91(95% CI,0.85-0.98)。COVID-19的发病率升高幅度更大,且在住院后持续时间更长:在这项研究中,未接种疫苗的人在接种严重的 COVID-19 后,精神疾病的发病率会升高长达一年。这些发现表明,接种疫苗可减轻 COVID-19 对精神健康的不良影响。
{"title":"COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People.","authors":"Venexia M Walker, Praveetha Patalay, Jose Ignacio Cuitun Coronado, Rachel Denholm, Harriet Forbes, Jean Stafford, Bettina Moltrecht, Tom Palmer, Alex Walker, Ellen J Thompson, Kurt Taylor, Genevieve Cezard, Elsie M F Horne, Yinghui Wei, Marwa Al Arab, Rochelle Knight, Louis Fisher, Jon Massey, Simon Davy, Amir Mehrkar, Seb Bacon, Ben Goldacre, Angela Wood, Nishi Chaturvedi, John Macleod, Ann John, Jonathan A C Sterne","doi":"10.1001/jamapsychiatry.2024.2339","DOIUrl":"10.1001/jamapsychiatry.2024.2339","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Associations have been found between COVID-19 and subsequent mental illness in both hospital- and population-based studies. However, evidence regarding which mental illnesses are associated with COVID-19 by vaccination status in these populations is limited.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine which mental illnesses are associated with diagnosed COVID-19 by vaccination status in both hospitalized patients and the general population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This study was conducted in 3 cohorts, 1 before vaccine availability followed during the wild-type/Alpha variant eras (January 2020-June 2021) and 2 (vaccinated and unvaccinated) during the Delta variant era (June-December 2021). With National Health Service England approval, OpenSAFELY-TPP was used to access linked data from 24 million people registered with general practices in England using TPP SystmOne. People registered with a GP in England for at least 6 months and alive with known age between 18 and 110 years, sex, deprivation index information, and region at baseline were included. People were excluded if they had COVID-19 before baseline. Data were analyzed from July 2022 to June 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Confirmed COVID-19 diagnosis recorded in primary care secondary care, testing data, or the death registry.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Adjusted hazard ratios (aHRs) comparing the incidence of mental illnesses after diagnosis of COVID-19 with the incidence before or without COVID-19 for depression, serious mental illness, general anxiety, posttraumatic stress disorder, eating disorders, addiction, self-harm, and suicide.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The largest cohort, the pre-vaccine availability cohort, included 18 648 606 people (9 363 710 [50.2%] female and 9 284 896 [49.8%] male) with a median (IQR) age of 49 (34-64) years. The vaccinated cohort included 14 035 286 individuals (7 308 556 [52.1%] female and 6 726 730 [47.9%] male) with a median (IQR) age of 53 (38-67) years. The unvaccinated cohort included 3 242 215 individuals (1 363 401 [42.1%] female and 1 878 814 [57.9%] male) with a median (IQR) age of 35 (27-46) years. Incidence of most outcomes was elevated during weeks 1 through 4 after COVID-19 diagnosis, compared with before or without COVID-19, in each cohort. Incidence of mental illnesses was lower in the vaccinated cohort compared with the pre-vaccine availability and unvaccinated cohorts: aHRs for depression and serious mental illness during weeks 1 through 4 after COVID-19 were 1.93 (95% CI, 1.88-1.98) and 1.49 (95% CI, 1.41-1.57) in the pre-vaccine availability cohort and 1.79 (95% CI, 1.68-1.90) and 1.45 (95% CI, 1.27-1.65) in the unvaccinated cohort compared with 1.16 (95% CI, 1.12-1.20) and 0.91 (95% CI, 0.85-0.98) in the vaccinated cohort. Elevation in incidence was higher and persisted longer after hospitalization for COVID-19.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conc","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Psychotherapy in MDMA-Assisted Psychotherapy. 摇头丸辅助心理疗法中的心理疗法。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2887
Ioana Alina Cristea, Pim Cuijpers, Joar Øveraas Halvorsen
{"title":"The Psychotherapy in MDMA-Assisted Psychotherapy.","authors":"Ioana Alina Cristea, Pim Cuijpers, Joar Øveraas Halvorsen","doi":"10.1001/jamapsychiatry.2024.2887","DOIUrl":"10.1001/jamapsychiatry.2024.2887","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Text and Supplement. 正文和补编中的错误。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.3166
{"title":"Errors in Text and Supplement.","authors":"","doi":"10.1001/jamapsychiatry.2024.3166","DOIUrl":"10.1001/jamapsychiatry.2024.3166","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":null,"pages":null},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11425186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1